Shares of AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $14.20.
A number of analysts have commented on ABCL shares. KeyCorp restated an “overweight” rating and set a $5.00 price target (down from $7.00) on shares of AbCellera Biologics in a research report on Thursday, July 11th. Benchmark downgraded AbCellera Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 20th.
Read Our Latest Report on AbCellera Biologics
Institutional Inflows and Outflows
AbCellera Biologics Stock Down 1.6 %
ABCL stock opened at $2.39 on Tuesday. The firm’s 50-day simple moving average is $2.82 and its 200 day simple moving average is $3.64. The stock has a market cap of $702.79 million, a PE ratio of -4.60 and a beta of 0.37. AbCellera Biologics has a fifty-two week low of $2.36 and a fifty-two week high of $6.05.
AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. AbCellera Biologics had a negative return on equity of 13.40% and a negative net margin of 463.77%. The company had revenue of $7.30 million during the quarter, compared to analyst estimates of $10.12 million. During the same quarter in the previous year, the firm posted ($0.11) EPS. The firm’s quarterly revenue was down 27.7% on a year-over-year basis. Equities analysts forecast that AbCellera Biologics will post -0.55 EPS for the current fiscal year.
About AbCellera Biologics
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Featured Articles
- Five stocks we like better than AbCellera Biologics
- How to Find Undervalued Stocks
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- What Are Dividend Champions? How to Invest in the Champions
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.